IMS 2025: Patient perceptions of frailty and its assessment in those living with myeloma
Published:
One of the strongest messages from patients was that being labelled as ‘frail’ can feel limiting. Patients were aware that the label may restrict access to high-dose therapy and stem cell transplantation (HDT-SCT) or clinical trials, raising concerns that they could miss out on treatments that might extend life. The term itself also sparked discomfort. Patients associated ‘frailty’ with loss of independence, vulnerability and a reduced sense of identity – showing how language alone can influence confidence and decision-making.
Sign up and become a member of the Myeloma UK HCP Hub
Access exclusive content like this and join in the conversation.
Already have an account?